Alliancebernstein L.P. Iveric Bio, Inc. Transaction History

Alliancebernstein L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	SELL	$26.24 - $39.63 $55 Million - $83.1 Million	-2,096,250 Reduced 51.54%	1,970,785 $77.5 Million
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $3.08 Million - $4.05 Million	-164,882 Reduced 3.9%	4,067,035 $99 Million
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $32.3 Million - $44.8 Million	1,870,847 Added 79.24%	4,231,917 $90.6 Million
Q3 2022 Nov 15, 2022	BUY	$9.4 - $18.59 $21.2 Million - $41.9 Million	2,255,770 Added 2142.23%	2,361,070 $42.4 Million
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $22,799 - $47,250	2,500 Added 2.43%	105,300 $1.01 Million
Q1 2022 May 13, 2022	BUY	$12.15 - $16.83 $3,645 - $5,048	300 Added 0.29%	102,800 $1.73 Million
Q3 2021 Nov 10, 2021	BUY	$7.07 - $17.5 $114,534 - $283,500	16,200 Added 18.77%	102,500 $1.67 Million
Q2 2021 Jul 30, 2021	BUY	$5.69 - $7.17 $95,592 - $120,456	16,800 Added 24.17%	86,300 $545,000
Q1 2021 May 06, 2021	SELL	$5.08 - $6.89 $29,972 - $40,651	-5,900 Reduced 7.82%	69,500 $430,000
Q2 2020 Aug 13, 2020	BUY	$3.06 - $6.6 $230,724 - $497,640	75,400 New	75,400 $385,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.